Spasmodic-torticollis - Pipeline Insight, 2024

This “Spasmodic-torticollis - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Spasmodic-torticollis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Spasmodic-torticollis Understanding

Spasmodic-torticollis: Overview

Cervical dystonia, also known as spasmodic torticollis, is a rare neurological disorder that originates in the brain. It is the most common form of focal dystonia in an office setting. Cervical dystonia is characterized by involuntary muscle contractions in the neck that cause abnormal movements and postures of the neck and head. In some cases, these abnormal contractions may be sustained or continuous; in others, they may be present as spasms that can resemble tremor. The severity of cervical dystonia can vary, but the disorder can cause significant pain and discomfort as well as difficulty due to the abnormal postures. It can affect quality of life and activities of daily living including employment. Cervical dystonia typically begins in middle age, and rarely begins in adolescence and young adulthood.

Spasmodic-torticollis - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasmodic-torticollis pipeline landscape is provided which includes the disease overview and Spasmodic-torticollis treatment guidelines. The assessment part of the report embraces, in depth Spasmodic-torticollis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasmodic-torticollis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Spasmodic-torticollis R&D. The therapies under development are focused on novel approaches to treat/improve Spasmodic-torticollis.

Spasmodic-torticollis Emerging Drugs Chapters

This segment of the Spasmodic-torticollis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spasmodic-torticollis Emerging Drugs

Daxibotulinumtoxin A: Revance TherapeuticsDaxibotulinumtoxinA for Injection is an investigational agent that has not been approved by the FDA. It is a Acetylcholine inhibitor which is being developed by Revance Therapeutics. In November 2021, Revance announced positive results from the Phase 3 ASPEN-OLS trial for the treatment of adults with cervical dystonia, an open-label, long-term safety trial during which subjects were eligible to receive up to 4 treatments over a 52-week period. The results support the potential use of DaxibotulinumtoxinA for Injection, if approved, as a new treatment option for cervical dystonia where duration is a significant unmet need.

ABP-450: AEON BiopharmaABP-450 contains a 900 kDa botulinum toxin type-A complex produced by the bacterium Clostridium botulinum. Botulinum toxin type-A specifically blocks the release of peripheral neurotransmitters and neuropeptide at presynaptic nerve terminals by cleaving SNAP-25, a protein integral to the successful docking and release of these substances from vesicles situated within the nerve endings. AEON Biopharma licenses ABP-450 from Daewoong and possesses exclusive development and distribution rights for ABP-450 for therapeutic indications in the United States, Canada, the European Union, inclusive of the United Kingdom, and certain other international territories.

Spasmodic-torticollis: Therapeutic Assessment

This segment of the report provides insights about the different Spasmodic-torticollis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Spasmodic-torticollis

There are approx. 3+ key companies which are developing the therapies for Spasmodic-torticollis. The companies which have their Spasmodic-torticollis drug candidates in the most advanced stage, i.e. phase III include, Revance Therapeutics.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Spasmodic-torticollis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Spasmodic-torticollis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Spasmodic-torticollis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasmodic-torticollis drugs.

Spasmodic-torticollis Report Insights

• Spasmodic-torticollis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spasmodic-torticollis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Spasmodic-torticollis drugs?
• How many Spasmodic-torticollis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasmodic-torticollis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spasmodic-torticollis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spasmodic-torticollis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Revance Therapeutics
• Medytox
• Addex Pharmaceuticals
• AEON Biopharma

Key Products

• Daxibotulinumtoxin A
• Meditoxin
• Dipraglurant
• ABP-450

This product will be delivered within 2 business days.